ABOUT CELYAD ONCOLOGY

Celyad Oncology is a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer.

More Info About Celyad ONCOLOGY

Latest News

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Celyad Oncology Provides Strategic Update

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

Celyad Oncology Announces Leadership Updates

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline

Celyad Oncology @celyadsa ·

10 Nov

We've just published our third quarter financial results and business updates- read more here: https://buff.ly/3NWjDH2 $CYAD

Twitter 1590684706021859328

Celyad Oncology @celyadsa ·

21 Oct

shRNA has many unique capabilities to develop allogeneic CAR Ts, including the ability to multiplex. Learn more about the benefits of multiplexing shRNA with our new fact sheet here: https://buff.ly/3auLCet

Twitter 1583483759570976768

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.